Advisory Committee on Heritable Disorders in Newborns and Children, 48103-48104 [2017-22313]
Download as PDF
ethrower on DSK3G9T082PROD with NOTICES
Federal Register / Vol. 82, No. 198 / Monday, October 16, 2017 / Notices
In addition to the partnerships above,
HRSA is seeking comment on state or
regional initiatives to consider when
establishing the qualifying standards for
the CHGME Quality Bonus System, as
well as suggestions for how to
distinguish between levels of
engagement and performance in a
meaningful way.
Documentation: To receive a quality
bonus payment based upon engagement
in state- or regional-level pediatric
health care transformation, CHGME
hospitals would be required to submit a
letter from the lead organization, which
could include the project director for a
HRSA-supported program or the state
Medicaid Director, confirming
participation by the children’s hospital
in the program and delineating the roles
and responsibilities of the children’s
hospital in the program activities. In
addition, CHGME hospitals would be
required to submit a brief narrative
statement describing how CHGME
trainees are integrated into state- or
regional-level pediatric health care
transformation activities and the
expected benefits for trainees and the
health systems served by the children’s
hospital. HRSA is seeking comment on
this proposed approach including
opportunities to limit burden and
streamline the documentation to
determine whether applicants meet
standards and distinguish among levels
of engagement and performance.
Payment Structure: HRSA proposes
that CHGME hospitals that meet the
standards receive a portion of the
available funds for the CHGME Quality
Bonus System. HRSA proposes a three
tiered payment structure to recognize
the different annual payment levels
received by CHGME hospitals. Hospitals
that meet the Quality Bonus Systems
standards will be evenly divided into
three tiers based on their combined
direct and indirect fiscal year payment
amounts, as calculated per the
established CHGME program formulas:
Tier 1: Hospitals that qualify for the
quality bonus payment that are in the
lowest third among hospitals that
qualify for the quality bonus payment of
calculated CHGME annual payments
will receive a base payment.
Tier 2: Hospitals that qualify for the
quality bonus payment that are in the
middle third will receive two times the
base payment.
Tier 3: Hospitals that qualify for the
quality bonus payment that are in the
highest third will receive three times the
base payment.
The base payment rate would be
determined from the total amount
available and the number of hospitals
that qualify for the CHGME Quality
VerDate Sep<11>2014
16:59 Oct 13, 2017
Jkt 244001
Bonus System in a fiscal year. HRSA
would also seek to recognize the
hospital’s level of engagement or
performance in the bonus amount.
HRSA is also interested in gathering
views and suggestions on whether any
of the existing information that
hospitals already report to the Centers of
Medicare and Medicaid Services, HRSA,
accrediting bodies, and others could be
used to measure the performance of
GME programs and related health
outcomes for FY 2019 or subsequent
years. This could be individual
measures or combinations of measures
that are reported to different entities.
Quality Bonus Payment in FY 2020 and
Beyond—Areas for Public Comment
In future years, HRSA will refine the
CHGME Quality Bonus System to reflect
the feedback received from
stakeholders, as well as advancements
in the development of standardized
GME quality measures. To that end,
HRSA also is requesting comments on
several areas of the Quality Bonus
System that will be implemented in FY
2020 and beyond. For long-term
implementation, HRSA seeks public
comments on the following areas:
CHGME Hospital Eligibility: HRSA
proposes to include all eligible CHGME
hospitals, including those newly
qualified, as eligible entities for the
CHGME Quality Bonus System.
Quality Bonus System Measures:
HRSA is seeking comment on
appropriate GME outcome measures
that can assess and distinguish
performance in meaningful ways. HRSA
is considering several GME outcome
measures including resident specialty
outcomes (e.g., number of graduates in
high need pediatric specialties), resident
service outcomes (e.g., service to high
need rural or underserved
communities), and children’s hospital
quality outcomes. As noted above, these
measures could be existing measures
that hospitals already report or new
ones that would be developed or
improved for use in determining quality
bonuses.
Data Sources: HRSA is seeking
comment on available data sources on
which to base the Quality Bonus
System. HRSA is requesting comment
on data sources that are publicly
available, will streamline reporting
requirements, and will limit burden on
CHGME programs.
Tiering of Quality Bonus Payments:
HRSA is requesting comments on
payment structures to recognize
hospitals according to their level of
engagement and/or outcomes while also
taking into account the different size of
GME programs. The goal is for payment
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
48103
structures to recognize the quality of
hospitals’ programs considering the
different circumstances in which
different children’s hospitals operate
(e.g., patient severity, size of training
programs, number of specialties trained,
etc.)
Frequency of Review: HRSA plans to
review and update the CHGME Quality
Bonus System standards regularly to
reflect changes in GME and advances in
measuring GME outcomes.
Dated: October 5, 2017
George Sigounas,
Administrator.
[FR Doc. 2017–22381 Filed 10–13–17; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Service
Administration
Advisory Committee on Heritable
Disorders in Newborns and Children
Health Resources and Service
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, notice
is hereby given that a meeting is
scheduled for the Advisory Committee
on Heritable Disorders in Newborns and
Children (ACHDNC). This meeting will
be open to the public but advance
registration is required. Please register
online at https://
www.achdncmeetings.org/ by 12:00 p.m.
Eastern Time on November 6, 2017.
Information about the ACHDNC can be
obtained by accessing the following
Web site: https://www.hrsa.gov/
advisorycommittees/mchbadvisory/
heritabledisorders/.
DATES: The meeting will be held on
Wednesday, November 8, 2017, 9:30
a.m. to 5:00 p.m. Eastern Time and
Thursday, November 9, 2017, 9:30 a.m.
to 3:00 p.m. Eastern Time (meeting
times are tentative).
ADDRESSES: This meeting will be held
in-person at 5600 Fishers Lane, 5th
Floor Pavilion, Rockville, MD 20857.
The meeting will also be accessible via
Webcast. Instructions on how to access
the meeting via Webcast will be
provided upon registration. Please note,
the 5600 Fishers Lane building requires
security screening on entry. Visitors
must provide a driver’s license,
passport, or other form of governmentissued photo identification to be granted
entry into the facility. Non-US Citizens
planning to attend in person will need
SUMMARY:
E:\FR\FM\16OCN1.SGM
16OCN1
ethrower on DSK3G9T082PROD with NOTICES
48104
Federal Register / Vol. 82, No. 198 / Monday, October 16, 2017 / Notices
to provide additional information to
HRSA by October 24, 2017, 12:00 p.m.
Eastern Time. Please see contact
information below.
FOR FURTHER INFORMATION CONTACT:
Anyone requesting information
regarding the ACHDNC should contact
Ann Ferrero, Maternal and Child Health
Bureau (MCHB), HRSA, in one of three
ways: (1) Send a request to the following
address: Ann Ferrero, MCHB, HRSA
5600 Fishers Lane, Room 18N100C,
Rockville, MD 20857; (2) call 301–443–
3999; or (3) send an email to: AFerrero@
hrsa.gov.
SUPPLEMENTARY INFORMATION: The
ACHDNC provides advice to the
Secretary of HHS on the development of
newborn screening activities,
technologies, policies, guidelines, and
programs for effectively reducing
morbidity and mortality in newborns
and children having, or at risk for,
heritable disorders. In addition,
ACHDNC’s recommendations regarding
inclusion of additional conditions and
inherited disorders for screening which
have been adopted by the Secretary are
then included in the Recommended
Uniform Screening Panel (RUSP).
Conditions listed on the RUSP
constitute part of the comprehensive
preventive health guidelines supported
by HRSA for infants and children under
section 2713 of the Public Health
Service Act, codified at 42 U.S.C.
300gg–13. Under this provision, nongrandfathered health plans are required
to cover screenings included in the
HRSA-supported comprehensive
guidelines without charging a copayment, co-insurance, or deductible for
plan years (i.e., policy years) beginning
on or after the date that is one year from
the Secretary’s adoption of the
condition for screening.
The meeting agenda will include: (1)
An update on states’ progress toward
the newborn screening timeliness goals
outlined by the Committee; (2) a
presentation on phase 2 of the spinal
muscular atrophy evidence review; (3)
presentations on newborn screening
topics such as the clinical and public
health impact of Severe Combined
Immunodeficiency (SCID), carrier status
in the context of newborn screening,
and a review of long term follow up in
newborn screening; and (4) updates
from the Laboratory Standards and
Procedures workgroup, Follow-up and
Treatment workgroup, and Education
and Training workgroup. The
Committee will not be voting on a
proposed addition of a condition to the
RUSP. Agenda items are subject to
change. The final meeting agenda will
be available 2 days prior to the meeting
VerDate Sep<11>2014
16:59 Oct 13, 2017
Jkt 244001
on the Committee’s Web site: https://
www.hrsa.gov/advisorycommittees/
mchbadvisory/heritabledisorders.
Members of the public will have the
opportunity to provide comments. All
comments are part of the official
Committee record. To submit written
comments or request time for an oral
comment at the meeting, please register
online by 11:59 p.m. Eastern Time on
November 2, 2017, at https://
www.achdncmeetings.org/. To ensure
all individuals who have registered and
requested time for oral comments are
accommodated, the allocated time for
comments may be limited. Individuals
associated with groups or who plan to
provide comments on similar topics
may be asked to combine their
comments and present them through a
single representative. No audiovisual
presentations are permitted. Written
comments should identify the
individual’s name, address, email,
telephone number, professional or
organization affiliation, background or
area of expertise (i.e., parent, family
member, researcher, clinician, public
health, etc.) and the topic/subject
matter.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify Ann Ferrero using the address
and phone number above at least 10
days prior to the meeting.
Amy McNulty,
Acting Director, Division of the Executive
Secretariat.
[FR Doc. 2017–22313 Filed 10–13–17; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Planning Grant (R34) and Implementation
Cooperative Agreement (U01).
Date: November 6–9, 2017.
Time: 9:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892,
(Telephone Conference Call).
Contact Person: Geetanjali Bansal, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3G49, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9834,
Bethesda, MD 20892–9834, (240) 669–5073,
geetanjali.bansal@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 10, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–22259 Filed 10–13–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Translational Studies on Adducts For Cancer
Risk Identification and Prevention.
Date: November 8, 2017.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W108, Rockville, MD 20850, (Telephone
Conference Call).
E:\FR\FM\16OCN1.SGM
16OCN1
Agencies
[Federal Register Volume 82, Number 198 (Monday, October 16, 2017)]
[Notices]
[Pages 48103-48104]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-22313]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Service Administration
Advisory Committee on Heritable Disorders in Newborns and
Children
AGENCY: Health Resources and Service Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, notice
is hereby given that a meeting is scheduled for the Advisory Committee
on Heritable Disorders in Newborns and Children (ACHDNC). This meeting
will be open to the public but advance registration is required. Please
register online at https://www.achdncmeetings.org/ by 12:00 p.m. Eastern
Time on November 6, 2017. Information about the ACHDNC can be obtained
by accessing the following Web site: https://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/.
DATES: The meeting will be held on Wednesday, November 8, 2017, 9:30
a.m. to 5:00 p.m. Eastern Time and Thursday, November 9, 2017, 9:30
a.m. to 3:00 p.m. Eastern Time (meeting times are tentative).
ADDRESSES: This meeting will be held in-person at 5600 Fishers Lane,
5th Floor Pavilion, Rockville, MD 20857. The meeting will also be
accessible via Webcast. Instructions on how to access the meeting via
Webcast will be provided upon registration. Please note, the 5600
Fishers Lane building requires security screening on entry. Visitors
must provide a driver's license, passport, or other form of government-
issued photo identification to be granted entry into the facility. Non-
US Citizens planning to attend in person will need
[[Page 48104]]
to provide additional information to HRSA by October 24, 2017, 12:00
p.m. Eastern Time. Please see contact information below.
FOR FURTHER INFORMATION CONTACT: Anyone requesting information
regarding the ACHDNC should contact Ann Ferrero, Maternal and Child
Health Bureau (MCHB), HRSA, in one of three ways: (1) Send a request to
the following address: Ann Ferrero, MCHB, HRSA 5600 Fishers Lane, Room
18N100C, Rockville, MD 20857; (2) call 301-443-3999; or (3) send an
email to: AFerrero@hrsa.gov.
SUPPLEMENTARY INFORMATION: The ACHDNC provides advice to the Secretary
of HHS on the development of newborn screening activities,
technologies, policies, guidelines, and programs for effectively
reducing morbidity and mortality in newborns and children having, or at
risk for, heritable disorders. In addition, ACHDNC's recommendations
regarding inclusion of additional conditions and inherited disorders
for screening which have been adopted by the Secretary are then
included in the Recommended Uniform Screening Panel (RUSP). Conditions
listed on the RUSP constitute part of the comprehensive preventive
health guidelines supported by HRSA for infants and children under
section 2713 of the Public Health Service Act, codified at 42 U.S.C.
300gg-13. Under this provision, non-grandfathered health plans are
required to cover screenings included in the HRSA-supported
comprehensive guidelines without charging a co-payment, co-insurance,
or deductible for plan years (i.e., policy years) beginning on or after
the date that is one year from the Secretary's adoption of the
condition for screening.
The meeting agenda will include: (1) An update on states' progress
toward the newborn screening timeliness goals outlined by the
Committee; (2) a presentation on phase 2 of the spinal muscular atrophy
evidence review; (3) presentations on newborn screening topics such as
the clinical and public health impact of Severe Combined
Immunodeficiency (SCID), carrier status in the context of newborn
screening, and a review of long term follow up in newborn screening;
and (4) updates from the Laboratory Standards and Procedures workgroup,
Follow-up and Treatment workgroup, and Education and Training
workgroup. The Committee will not be voting on a proposed addition of a
condition to the RUSP. Agenda items are subject to change. The final
meeting agenda will be available 2 days prior to the meeting on the
Committee's Web site: https://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders.
Members of the public will have the opportunity to provide
comments. All comments are part of the official Committee record. To
submit written comments or request time for an oral comment at the
meeting, please register online by 11:59 p.m. Eastern Time on November
2, 2017, at https://www.achdncmeetings.org/. To ensure all individuals
who have registered and requested time for oral comments are
accommodated, the allocated time for comments may be limited.
Individuals associated with groups or who plan to provide comments on
similar topics may be asked to combine their comments and present them
through a single representative. No audiovisual presentations are
permitted. Written comments should identify the individual's name,
address, email, telephone number, professional or organization
affiliation, background or area of expertise (i.e., parent, family
member, researcher, clinician, public health, etc.) and the topic/
subject matter.
Individuals who plan to attend and need special assistance, such as
sign language interpretation or other reasonable accommodations, should
notify Ann Ferrero using the address and phone number above at least 10
days prior to the meeting.
Amy McNulty,
Acting Director, Division of the Executive Secretariat.
[FR Doc. 2017-22313 Filed 10-13-17; 8:45 am]
BILLING CODE 4165-15-P